Highlights of Biotherapeutics and Higher-Throughput Protein Expression DVD
About the DVD:
Pipeline Three explores the pioneering world of protein-based therapeutics, from novel constructs to enhanced in vivo effects. The pipeline encompasses the state of the art in antibody and recombinant protein therapeutics, and provides a review of next generation therapeutics. The discovery, development and production of therapeutic proteins are also crucial activities in the protein engineering field. Pipeline Four provides the latest science and developments on topics covering all aspects of protein science, discovery, analysis, characterization, development and expression of these valuable and promising therapeutics.
About the Conference:
CHI’s 10th Annual PepTalk event features strong scientific programming comprising fourteen conferences within topic focused pipelines. The four distinct pipelines range from applying protein discovery research, to developing downstream protein expression, characterization, formulation, and production that ultimately leads to clinical applications. This event is designed with you in mind. Stay within a specific pipeline or track hop, and create a custom agenda to meet your research and networking needs.
This DVD includes the following tracks:
Targeting Genes, Engineering Vectors, Designing Constructs and Optimizing Clones
Choosing, Designing, and Optimizing Hosts and Platforms
Overcoming Protein Expression Challenges with Solutions
Recombinant Protein Therapeutics
Antibody Drug Products
About the DVD:
Over 270 Slides
Individual Copy: $345
Site License: $1380
Agenda At A Glance:
Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome
Daniel Gibson, Ph.D., Associate Professor, Synthetic Biology and Bioenergy Department, J. Craig Venter Institute
Recombinant Proteins for Targeting Intracellular Compartments of Cancer Cells
Waldemar Debinski, M.D., Ph.D., Director, Brain Tumor Center of Excellence; Head, Section of Tumor Biology, Department of Neurosurgery; Professor of Neurosurgery, Radiation Oncology and Cancer Biology, Wake Forest University
Health Sciences, Wake Forest Comprehensive Cancer Center
Significant Enhanced Expression and Solubility of Human Proteins in Escherichia coli by Fusion with Protein S from Myxococcus xanthus
Masayori Inouye, Ph.D., Department of Biochemistry, Robert Wood Johnson Medical School
Synthetic Polymers with Antibody-Like Affinity that Function in vitro and in vivo
Kenneth Shea, Ph.D., Professor, Chemistry and Chemical Engineering, Biological and Materials Science, University of California, Irvine
Membrane Proteins in the Service of Human Health
Robert Stroud, Ph.D., Professor, Biochemistry & Biophysics; Pharmaceutical Chemistry, University of California, San Francisco
High-Speed NMR Analysis of Human Membrane Proteins Expressed by Cell-Free Synthesis
Senyon Choe, Ph.D., Professor, Structural Biology Laboratory, Salk Institute & Joint Center for Biosciences
Dr. Daniel Gibson is an Associate Professor in the Synthetic Genomics department at the J. Craig Venter Institute in Rockville, MD. He had been co-leading the group's effort to synthesize a bacterial cell. Along the way he has pioneered methods that are instrumental to the synthetic biology field including the development of robust protocols for the assembly of overlapping DNA fragments into genome-size pieces. Prior to joining the JCVI, Dan earned his Ph.D. in molecular biology from the University of Southern California. While there, he studied surveillance mechanisms known as "checkpoints", which are significant in our understanding of cancer development. Before earning his Ph.D., he earned his Bachelor’s degree in Biological Sciences from the State University of New York at Buffalo. He joined the JCVI in 2004 and is where he began his Post-Doctoral studies.
Dr. Waldemar Debinski is the Director of the Brain Tumor Center of Excellence at the Wake Forest University School of Medicine. He received his Ph.D. from McGill University and his Pd.F. from the NCI/NIH. Dr. Debinski holds several professional memberships, including a membership in the USAMRMC tuberous scierosis research program, a reviewer ad hoc for NIH/Nci specialized programs in excellence, the Prostate Cancer Foundation of Australia, and the Samantha Dickson Brain Tumour Trust. In addition, he has produced over 100 peer-reviewed publications in the field of translational canter research.
Dr. Masayori Inouye, Distinguished Professor at Robert Wood Johnson Medical School, is a leading scientist in the field of molecular biology and biochemistry, who has made a number of important discoveries in life science. He received his Ph.D. at Osaka University, Japan. In 2008, he was appointed as Distinguished Professor and currently is a resident member of the Center for Advanced Biotechnology and Medicine. He is a member of prestigious institutions such as, the American Academy of Arts and Sciences and the American Academy of Microbiology. Dr. Inouye’s research has led to significant advances in the fields of protein folding, bacterial stress response and gene regulation. Most notably, he discovered for the first time a new principle of gene regulation by RNA in 1984, which opened an unprecedented avenue for engineering gene expression from bacteria to humans. In addition to RNA-based mRNA interference, he recently made another important discovery that gene expression can be regulated by protein-based mRNA interference by enzymes, mRNA interferases, destroying specific mRNAs in living cells. This finding leads to novel therapeutic method for cancer and AIDS.
Dr. Kenneth Shea is a Professor of Chemistry in the School of Physical Sciences at the University of California, Irvine. He received his Ph.D. from Pennsylvania State University. His research interests include synthetic organic, polymer, and materials chemistry. He has earned a number of academic awards, including Regents Faculty Fellow, School of Physics Sciences Distinguished Teaching Award, NIH Senior International Fellow, Winston Churchill College Overseas Fellow (Cambridge University), Fellow if the American Association for the Advancement of Science, and the Arthur C. Cope Scholar Award.
Dr. Robert Stroud is a Professor of Pharmaceutical Chemistry and Biochemistry & BioPhysics at the University of California, San Francisco. He was the first to discover fundamental mechanisms of transmembrane proteins by 'Aquaporins' at atomic resolution. These included GlpF, AqpZ, the eye lens AQP0, the H2S channel, and the essential glycerol channel of the malaria parasite P.falciparum. He defined the structure and regulatory mechanisms of the ammonia channel AmtB and the 'Rh factors'. He revealed the atomic basis for 'signal sequence' dependant membrane protein synthesis, signaling by EPO (erythropoietin) via its receptors. Stroud also determined the mechanisms of enzyme drug targets thymidylate synthase, HIV protease, HIV integrase, and KSHV protease and used these to facilitate drug discovery for human health.
Dr. Senyon Choe is a Professor at the Structural Biology Laboratory at the Salk Institute in La Jolla, CA. He received his Ph.D. in Biophysics from the University of California, San Francisco and Berkeley. Aside from his position at UCSD, he is currently the founding director of the joint Center for Biosciences in Songdo Korea, as well as a founding scientist of Implenitude, Inc. His research interests include structural and functional studies of macromolecular assembly and recognition related to biology at the membrane interface, in particular, transmembrane signaling in TGF-beta family receptor; ion conductance and permeation, assembly of voltage-gated K channels by computational, x-ray crystallography, biophysical methods and site-specific mutagenesis. In addition, Dr. Choe researches protein engineering and protein therapeutics for developmental and cancer disorders.